Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas.
Frank KroschinskyDenise RölligBarbara RiemerMichael KramerRainer OrdemannJohannes ScheteligMartin BornhäuserGerhard EhningerMathias HänelPublished in: Journal of cancer research and clinical oncology (2019)
An improvement in efficacy could not be observed after modified DHAP regimen; however, manageable toxicity and reduced renal complications suggest further investigation. The study, however, also underlines the need for new concepts in the management of advanced and high-risk lymphomas.